JW Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Operating Revenue	742,847	719,376	748,527	684,351	606,585	547,336	Upgrade
Other Revenue	-0	-0	-0	-	-	-	Upgrade
Revenue	742,847	719,376	748,527	684,351	606,585	547,336	Upgrade
Revenue Growth (YoY)	0.10%	-3.89%	9.38%	12.82%	10.82%	7.04%	Upgrade
Cost of Revenue	398,659	395,878	412,984	396,397	372,209	369,810	Upgrade
Gross Profit	344,188	323,498	335,542	287,955	234,376	177,526	Upgrade
Selling, General & Admin	213,361	210,610	204,728	182,652	171,220	149,035	Upgrade
Research & Development	42,646	36,237	33,671	33,736	19,884	22,943	Upgrade
Operating Expenses	252,366	240,766	238,911	227,464	203,528	178,849	Upgrade
Operating Income	91,822	82,733	96,631	60,490	30,848	-1,323	Upgrade
Interest Expense	-10,033	-10,033	-12,562	-9,387	-7,337	-7,587	Upgrade
Interest & Investment Income	4,962	4,962	6,322	5,814	1,981	632.79	Upgrade
Earnings From Equity Investments	1,357	1,387	621.06	-955.41	-1,149	-1,924	Upgrade
Currency Exchange Gain (Loss)	1,087	1,087	-1,817	-2,300	-925.96	-2,214	Upgrade
Other Non Operating Income (Expenses)	-514.03	2,253	-36,102	5,425	-1,191	-777.66	Upgrade
EBT Excluding Unusual Items	88,681	82,390	53,095	59,088	22,227	-13,193	Upgrade
Gain (Loss) on Sale of Investments	790.9	790.9	2,830	-8,908	-646.8	-	Upgrade
Gain (Loss) on Sale of Assets	464.91	464.91	-1,088	3.28	-1,048	-12.24	Upgrade
Asset Writedown	-1,476	-1,476	-	-4,821	-	-	Upgrade
Other Unusual Items	249.74	249.74	-	-	-	-	Upgrade
Pretax Income	88,711	82,420	54,836	45,362	20,533	-13,205	Upgrade
Income Tax Expense	36,664	17,379	16,406	15,509	21,974	2,070	Upgrade
Earnings From Continuing Operations	52,047	65,040	38,430	29,853	-1,441	-15,275	Upgrade
Minority Interest in Earnings	-	-	-1,424	2,039	473.6	34.19	Upgrade
Net Income	52,047	65,040	37,006	31,892	-967.85	-15,241	Upgrade
Preferred Dividends & Other Adjustments	1,970	4,259	-	-	-	-	Upgrade
Net Income to Common	50,077	60,781	37,006	31,892	-967.85	-15,241	Upgrade
Net Income Growth	45.98%	75.75%	16.04%	-	-	-	Upgrade
Shares Outstanding (Basic)	23	23	24	23	23	23	Upgrade
Shares Outstanding (Diluted)	23	23	24	23	23	23	Upgrade
Shares Change (YoY)	-2.44%	-2.01%	2.49%	0.07%	-0.05%	0.04%	Upgrade
EPS (Basic)	2156.98	2605.86	1554.67	1373.14	-41.70	-656.37	Upgrade
EPS (Diluted)	2156.98	2605.86	1554.67	1373.14	-41.70	-656.37	Upgrade
EPS Growth	50.19%	67.62%	13.22%	-	-	-	Upgrade
Free Cash Flow	42,151	71,079	59,871	46,845	10,657	50,667	Upgrade
Free Cash Flow Per Share	1815.58	3047.37	2515.25	2016.97	459.20	2182.01	Upgrade
Dividend Per Share	450.000	450.000	-	-	-	-	Upgrade
Gross Margin	46.33%	44.97%	44.83%	42.08%	38.64%	32.44%	Upgrade
Operating Margin	12.36%	11.50%	12.91%	8.84%	5.08%	-0.24%	Upgrade
Profit Margin	6.74%	8.45%	4.94%	4.66%	-0.16%	-2.79%	Upgrade
Free Cash Flow Margin	5.67%	9.88%	8.00%	6.84%	1.76%	9.26%	Upgrade
EBITDA	110,596	101,834	119,206	77,327	46,960	19,365	Upgrade
EBITDA Margin	14.89%	14.16%	15.93%	11.30%	7.74%	3.54%	Upgrade
D&A For EBITDA	18,774	19,101	22,575	16,836	16,112	20,688	Upgrade
EBIT	91,822	82,733	96,631	60,490	30,848	-1,323	Upgrade
EBIT Margin	12.36%	11.50%	12.91%	8.84%	5.08%	-0.24%	Upgrade
Effective Tax Rate	41.33%	21.09%	29.92%	34.19%	107.02%	-	Upgrade
Advertising Expenses	-	24,252	22,690	22,673	18,416	15,067	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.